Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday. The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use. The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said. In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease. |
Judge in Trump's classified documents case cancels May trial dateHow major US stock indexes fared Tuesday, 5/7/2024Driver dies after vehicle crashes into White House gateActivist says US congressman knocked cellphone from her hand as she asked about IsraelScientists discover remains of a 'buried planet' deep inside EARTHZelensky 'assassination plot foiled' as Ukraine detains two of its own counterDortmund's Reus hopes to sign off in styleUkraine says it foiled Russian plot to assassinate ZelenskyyRevealed: Ministers considered a RwandaJudge: Alabama groups can sue over threat of prosecution for helping with abortion travel